Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe...

Area of Science:

• Pharmacology
• Critical Care Medicine
• Infectious Diseases

Background:

• Remdesivir is an antiviral medication known to accelerate recovery in COVID-19 patients.
• Limited data exists on remdesivir pharmacokinetics in severe COVID-19 cases requiring extracorporeal membrane oxygenation (ECMO).
• Understanding drug behavior in ECMO patients is crucial for optimizing treatment.

Observation:

• A case study of a 63-year-old male with severe COVID-19 on mechanical ventilation and ECMO was conducted.
• Remdesivir was administered over ten days with specific loading and daily dosages.
• Pharmacokinetic analysis was performed, monitoring plasma concentrations and serum creatinine levels.

Findings:

• Plasma concentrations of remdesivir and its metabolite GS-441524 were measured at 4 and 18 hours post-administration.
• The calculated half-life for remdesivir was 3.2 hours and for GS-441524 was 35.1 hours.
• Serum creatinine remained within normal limits throughout the treatment period.

Implications:

• The findings provide initial pharmacokinetic data for remdesivir in ECMO-supported COVID-19 patients.
• Continuous monitoring of remdesivir and GS-441524 plasma concentrations may be warranted in this critical patient population.
• This data can inform future dosing strategies and therapeutic drug monitoring for remdesivir in ECMO settings.